LunaVax Insights: Nigeria sustains WHO milestone for vaccine production

A first for Africa: Nigeria sustains WHO’s ML3 status.

In August 2025, Nigeria became the first country in Africa to successfully sustain the World Health Organization’s Maturity Level 3 (ML3) for regulating medicines and vaccines. This milestone confirms that the country’s system is strong enough to support safe, local vaccine production, a step toward self-reliance and reduced dependence on imports.

For Nigeria, it means greater public trust, new jobs, and the ability to make vaccines at home.
For the world, it means Africa is building regulatory strength to secure its own vaccine future.

At LunaVax, we believe vaccine equity depends on both local manufacturing and last-mile delivery. With strong regulation comes stronger supply chains, lasting stability, and a healthier, more self-reliant Africa.